Bas Consulting Inc Sample Contracts

Aida Pharmaceuticals Inc – AIDA PHARMACEUTICALS INC. AND SUBSIDIARIES UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS CONTENTS (August 13th, 2008)

The accompanying unaudited pro forma combined financial statements are based upon the historical condensed balance sheets and condensed statements of operations of Aida Pharmaceuticals Inc. and subsidiaries ("AIDA" or the "Company") and Jiangsu Institute of Microbiology Co., Ltd. and subsidiaries ("JSIM"). The unaudited pro forma combined balance sheet has been prepared as if the acquisition occurred on March 31, 2008. The unaudited pro forma combined statements of operations for the year ended December 31, 2007 and for the three months ended March 31, 2008 have been prepared as if the acquisition had occurred on January 1, 2008 and 2007. The purchase price has been allocated to the Company's assets and liabilities based upon preliminary estimates of their respective fair values. The pro forma information may not be indicative of the results that actually would have occurred if the merger had been in effect from and on the dates indicated or which may be obtained in the future.

Aida Pharmaceuticals Inc – JIANGSU INSTITUTE OF MICROBIOLOGY CO., LTD. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2007 AND 2006 (August 13th, 2008)

We have audited the accompanying consolidated balance sheets of Jiangsu Institute of Microbiology Co., Ltd. and subsidiaries (the “Company”) as of December 31, 2007 and 2006, and the related consolidated statements of operations and comprehensive income, changes in shareholders’ equity and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

Aida Pharmaceuticals Inc – CLASS B REDEEMABLE COMMON STOCK WARRANT CERTIFICATE (January 3rd, 2008)

This Warrant Certificate and each Warrant represented hereby are issued pursuant to and are subject in all respects to the terms and conditions set forth in the Warrant Agreement (the "Warrant Agreement"), dated as of _______, 2007, by and among the Company and the Warrant Agent.

Aida Pharmaceuticals Inc – Press Release (November 26th, 2007)

SANTA MONICA, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA - News) today announced that it has filed its form 10Q for the period ended September 30, 2007. Net revenues totaled $7,373,770 for the quarter ended 9/20/07, an increase of 5% over the same period in 2006. Gross profit decreased by 2.66% due to an increase in Costs of Goods Sold. Most notably, sales from Aida's transfusion and injection forms of etimicin sulfate increased markedly. Gross profit margins for Aida remained very strong, decreasing slightly from 55.81% to 51.75%. Aida management expects the decrease in profits to be temporary. The Chinese pharmaceutical industry is in a state of transition due to policy changes by China's State Food and Drug Administration (SFDA). The new medicine tender system for hospitals in some areas in 2007 requires hospitals to purchase medicines and drugs directly from pharmaceutical manufacturers rather than distributors, which resulted in

Aida Pharmaceuticals Inc – WARRANT AGREEMENT (November 13th, 2007)

AGREEMENT, dated as of October __, 2007, (the “Agreement”) by and between AIDA PHARMACEUTICALS, INC., a Nevada corporation (the "Company"), and [__________], a [_______] corporation, as Warrant Agent (the "Warrant Agent").

Aida Pharmaceuticals Inc – CLASS A REDEEMABLE COMMON STOCK WARRANT CERTIFICATE (November 13th, 2007)

This Warrant Certificate and each Warrant represented hereby are issued pursuant to and are subject in all respects to the terms and conditions set forth in the Warrant Agreement (the "Warrant Agreement"), dated as of _____, 2007, by and among the Company and the Warrant Agent.

Aida Pharmaceuticals Inc – CLASS B REDEEMABLE COMMON STOCK WARRANT CERTIFICATE (November 13th, 2007)

This Warrant Certificate and each Warrant represented hereby are issued pursuant to and are subject in all respects to the terms and conditions set forth in the Warrant Agreement (the "Warrant Agreement"), dated as of _______, 2007, by and among the Company and the Warrant Agent.

Aida Pharmaceuticals Inc – Supplementary Share Purchase Agreement (July 24th, 2006)
Aida Pharmaceuticals Inc – Supplementary Share Purchase Agreement (July 24th, 2006)
Aida Pharmaceuticals Inc – CONSULTING AGREEMENT (July 5th, 2006)

This consulting agreement (this “Agreement”) is made the 5th day of June, 2006, by and between AIDA Pharmaceuticals,Inc., (the “Company”), and Ms. Qiao Bei (the “Consultant”).

Aida Pharmaceuticals Inc – CONSULTING AGREEMENT (July 5th, 2006)

This consulting agreement (this “Agreement”) is made the 5th day of June, 2006, by and between AIDA Pharmaceuticals,Inc., (the “Company”), and Mr. Zheng Zhigang (the “Consultant”).

Aida Pharmaceuticals Inc – 2006 Stock Grant and Option Plan 2006 NON-QUALIFIED STOCK GRANT AND OPTION PLAN (July 5th, 2006)
Aida Pharmaceuticals Inc – Share Transfer Agreement (April 14th, 2006)
Aida Pharmaceuticals Inc – AMENDED ARTICLES OF INCORPORATION OF BAS CONSULTING, INC. (March 7th, 2006)

Pursuant to NRS 78.385 and 78.390 of the Nevada Business Corporations Act, BAS Consulting, Inc., (the "Corporation") adopts the following Amendment and Restatement of its Articles of Incorporation by stating the following:

Bas Consulting Inc – Report of Independent Registered Public Accounting Firm (January 11th, 2006)

We have audited the accompanying consolidated balance sheets of Hangzhou Aida Pharmaceuticals Co., Ltd. and subsidiaries (the “Company”) as of December 31, 2004 and 2003 and the related consolidated statements of income and comprehensive income, changes in shareholders’ equity and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

Bas Consulting Inc – Independent Registered Public Accounting Firm’s Review Report (January 11th, 2006)

We have reviewed the condensed consolidated balance sheet of Hangzhou Aida Pharmaceuticals Co., Ltd. and subsidiaries as of September 30, 2005, and the related condensed consolidated statements of operations and cash flows for the nine months ended September 30, 2005 and 2004 and the condensed consolidated statements of changes in shareholders’ equity for the nine months ended September 30, 2005. These consolidated financial statements are the responsibility of the Company’s management.

Bas Consulting Inc – BAS CONSULTING INC. UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS CONTENTS (December 9th, 2005)
Bas Consulting Inc – HANGZHOU AIDA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2004 AND 2003 HANGZHOU AIDA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES CONTENTS (December 9th, 2005)
Bas Consulting Inc – HANGZHOU AIDA PHARMACEUTICALS CO., LTD. AND SUBSIDIARIES INTERIM FINANCIAL STATEMENTS CONTENTS (December 9th, 2005)
Bas Consulting Inc – SHARE EXCHANGE AGREEMENT (June 15th, 2005)

This Share Exchange Agreement, dated as of June 1, 2005, is made by and among BAS CONSULTING, INC., a Nevada corporation (the "Acquiror"), each of the Persons listed on Exhibit A hereto (collectively, the "Shareholders", and individually a "Shareholder"), and Earjoy Group Limited, incorporated under the laws of the British Virgin Islands (the “Company”).

Bas Consulting Inc – 2002 NON-STATUTORY STOCK OPTION PLAN (March 14th, 2003)

Exhibit 10.1 BAS CONSULTING, INC. 2002 NON-STATUTORY STOCK OPTION PLAN 1. Purpose of this Plan This Non-Statutory Stock Option Plan (the "Plan") is intended as an employment incentive, to aid in attracting and retaining in the employ or service of BAS Consulting, Inc. (the "Company"), a Nevada corporation, and any Affiliated Corporation, persons of experience and ability and whose services are considered valuable, to encourage the sense of proprietorship in such persons, and to stimulate the active interest of such persons in the development and success of the Company. This Plan provides for the issuance of non-statutory stock options ("NSOs" or "Options") which are not intended to qualify as "incentive stock options" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"). 2. Administration of this Plan The Company's Board of Directors ("Board") may app